A nurse holds a COVID-19 vaccine in Miami, Fla., in this file photograph. Joe Raedle/Getty Images
Pfizer reported a decline in revenue on Nov. 4, which it primarily attributed to lower sales for the company’s COVID-19 vaccine, Comirnaty, and COVID-19 drug, Paxlovid.
The company said it made $16.7 billion in revenue in the third quarter, down 7 percent from Q3 2024.
